Giselle Mosnaim

Giselle Mosnaim

Auto-generated profile, based on publicly available information

Giselle Mosnaim

Division of Allergy and Immunology, Department of Medicine, Northshore University Health System, Evanston, Illinois, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
GMGiselle S. Mosnaim
Giselle S. Mosnaim
DSDavid A. Stempel
David A. Stempel
CGCandy Gonzalez
Candy Gonzalez
BABrittany Adams
Brittany Adams
NBNaomi BenIsrael-Olive
Naomi BenIsrael-Olive
SSStanley Szefler
Stanley Szefler

1 September 2020 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
NHNathan Hare
Nathan Hare
PBPriya Bansal
Priya Bansal
SBSakina S. Bajowala
Sakina S. Bajowala
SAStuart L. Abramson
Stuart L. Abramson
SCSheva Chervinskiy
Sheva Chervinskiy
GMGiselle S. Mosnaim
Giselle S. Mosnaim

14 January 2025 in JAMA
Verified
Journal Article
Open access
PDF file
DRDaniel Rayner
Daniel Rayner
DFDario M. Ferri
Dario M. Ferri
GGGordon H. Guyatt
Gordon H. Guyatt
POPaul M. O’byrne
Paul M. O’byrne
RBRomina Brignardello-Petersen
Romina Brignardello-Petersen
DCDerek K. Chu
Derek K. Chu
Asthma has a global prevalence of 262 million people and is characterized by airway inflammation and variable airflow obstruction.1 Reliever inhalers, including bronchodilator-only relievers (short-acting β agonists [SABA]), such as albuterol, or inhaled corticosteroids (ICS) with either SABA or formoterol, are indicated for patients with asthma to acutely relieve symptoms of dyspnea, wheezing, or cough.1 Although the Global Initiative for Asthma (GINA)1 and the National Asthma Education and Prevention Program2 recommend ICS-formoterol as the preferred reliever over SABA alone, the US Food and Drug Administration (FDA) recently approved ICS-SABA as a reliever inhaler; the optimal asthma reliever remains unclear.3 Furthermore, guideline recommendations do not sufficiently differentiate between ICS-SABA and SABA-alone relievers, and the relative benefits of ICS-formoterol compared with ICS-SABA on clinical outcomes remain unclear.1,2 This systematic review evaluated inhaled relievers for improving outcomes in asthma.

29 June 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
GMGiselle S. Mosnaim
Giselle S. Mosnaim
JGJustin Greiwe
Justin Greiwe
SJSunit P. Jariwala
Sunit P. Jariwala
RPRoy Pleasants
Roy Pleasants
RMRajan Merchant
Rajan Merchant

30 November 2023 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
GMGiselle S. Mosnaim
Giselle S. Mosnaim
FHFlavia C.L. Hoyte
Flavia C.L. Hoyte
GSGuilherme Safioti
Guilherme Safioti
RBRandall Brown
Randall Brown
THTanisha D. Hill
Tanisha D. Hill
MWMichael E. Wechsler
Michael E. Wechsler
Digital health tools have been shown to help address challenges in asthma control, including inhaler technique, treatment adherence and short-acting beta2-agonist overuse. The maintenance and reliever Digihaler System (DS) comprises two Digihaler inhalers (fluticasone propionate/salmeterol and albuterol) with an associated patient App and web-based Dashboard. Clinicians can review patients' inhaler use and Digihaler inhalation parameter data to support clinical decision-making. CONNECT2 evaluated asthma control in participants using the DS versus standard-of-care (SoC) maintenance and reliever inhalers. Participants (≥13 years) with uncontrolled asthma (Asthma Control Test [ACT] score <19) were randomized 4:3 (open-label) to the DS (n = 210) or SoC (n = 181) for 24 weeks. The primary endpoint was the proportion of patients achieving well-controlled asthma (i.e., an ACT score ≥20 or increase from baseline of ≥3 units at Week 24). There was an 88.7% probability that participants using the DS would have greater odds of achieving improvement in asthma control compared with SoC after 24 weeks. Mean odds ratio (95% credible interval) for DS versus SoC was 1.35 (0.846-2.038), indicating a 35% higher odds of improved asthma control with the DS. The DS group had more clinician-participant interactions versus SoC, mainly addressing poor inhaler technique. DS participants' maintenance treatment adherence was good (Month 1: 79.2%; Month 6: 68.6%); reliever use decreased by 38.2% versus baseline. App and Dashboard usability were rated 'good'. The positive results in asthma control in this study after 24 weeks demonstrate the effectiveness of the DS in asthma management.

7 November 2022 in Respiratory Medicine
Verified
Journal Article
Closed access
RIRoy A. Pleasants II
Roy A. Pleasants II
ACAmy Hai Yan Chan
Amy Hai Yan Chan
GMGiselle Mosnaim
Giselle Mosnaim
RCRichard W. Costello
Richard W. Costello
RDRajiv Dhand
Rajiv Dhand
STStephen L Tilley
Stephen L Tilley